Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jun;43(2):299-321.
doi: 10.1016/j.cll.2023.03.004.

A New Landscape of Testing and Therapeutics in Metastatic Breast Cancer

Geetha Jagannathan  1 , Marissa J White  1 , Rena R Xian  2 , Leisha A Emens  3 , Ashley Cimino-Mathews  4
Affiliations
Review

A New Landscape of Testing and Therapeutics in Metastatic Breast Cancer

Geetha Jagannathan et al. Clin Lab Med. 2023 Jun.

Abstract

Predictive biomarker testing on metastatic breast cancer is essential for determining patient eligibility for targeted therapeutics. The National Comprehensive Cancer Network currently recommends assessment of specific biomarkers on metastatic tumor subtypes, including hormone receptors, HER2, and BRCA1/2 mutations, on all newly metastatic breast cancers subtypes; programmed death-ligand 1 on metastatic triple-negative carcinomas; and PIK3CA mutation status on estrogen receptor-positive carcinomas. In select circumstances mismatch repair protein deficiency and/or microsatellite insufficiency, tumor mutation burden, and NTRK translocation status are also testing options. Novel biomarker testing, such as detecting PIK3CA mutations in circulating tumor DNA, is expanding in this rapidly evolving arena.

Keywords: Biomarkers; Breast cancer; Companion diagnostic; Metastasis; PD-L1; Tumor mutation burden.

PubMed Disclaimer

Conflict of interest statement

Disclosure G. Jagannathan: None; M.J. White: None; R.R. Xian: None; L.A. Emens: honoraria from AbbVie, Amgen, Celgene, Chugai, GCPR, Gilead, Gritstone, MedImmune, Peregrine, Shionogi, and Syndax; honoraria and travel support from AstraZeneca, Bayer, MacroGenics, Replimune, and Vaccinex; travel support from Bristol Myers Squibb, Genentech/Roche, and Novartis; potential future stock from Molecuvax; institutional support from AbbVie, Aduro Biotech, AstraZeneca, the Breast Cancer Research Foundation, Bristol Myers Squibb, Bolt Therapeutics, Compugen, Corvus, CyTomX, the US Department of Defense, EMD Serono, Genentech, Maxcyte, Merck, the National Cancer Institute, the NSABP Foundation, SU2C, Silverback, Roche, the Translational Breast Cancer Research Consortium, Takeda, Tempest, and HeritX; royalties from Aduro Biotech; A. Cimino-Mathews: Research grants to institution from Bristol-Myers Squibb; consultancy/honoraria to self from Bristol-Myers Squibb and Roche.

Republished from